Coronavirus may have dominated the headlines last year, but Germany’s pharmaceutical companies were busy fighting disease on a number of fronts.
The German Association of Research-Based Pharmaceutical Companies (vfa) says that its members brought 32 medications with new active ingredients on the market in 2020. They include not only the Covid-19 vaccine developed by BioNTech and US partner Pfizer but also ten medications to combat cancer.
“With the first Covid-19 vaccine, companies and regulatory authorities have started to the turn the tide of the pandemic,” said vfa President Han Steutel in a statement. “At the same time, companies continued to bring out new medications for patients with other diseases in 2020.”
The vfa added that its members invest more than EUR 7 billion a year in medication research.